Arch Dis Child Fetal Neonatal Ed 92:F108-F112 doi:10.1136/adc.2006.099499
  • Original article

Cognitive outcome and cyclo-oxygenase-2 gene (−765 G/C) variation in the preterm infant

  1. D R Harding1,
  2. S E Humphries2,
  3. A Whitelaw3,
  4. N Marlow4,
  5. H E Montgomery2
  1. 1Peter Dunn Neonatal Intensive Care Unit, St Michael’s Hospital, Bristol, UK
  2. 2Cardiovascular Genetics, University College London, London, UK
  3. 3Department of Clinical Science, University of Bristol, Southmead Hospital, Bristol, UK
  4. 4School of Human Development, University of Nottingham, Nottingham, UK
  1. Correspondence to:
    D Harding
    St Michael’s NICU, University of Bristol, D level, St Michael’s Hospital, Bristol BS2 8EG, UK; david.harding{at}
  • Accepted 5 August 2006
  • Published Online First 11 August 2006


Background: Cyclo-oxygenase (COX) inhibition by indomethacin does not result in an improvement in long-term neurocognitive outcome, despite reducing the incidence of both severe intraventricular haemorrhage and white matter injury visible on ultrasound. Diffuse brain injury after preterm birth may have inflammatory origins. These two points suggest that, in the preterm brain, COX inhibition may have a dominant proinflammatory or neuropathological role. The inducible form of the COX2 gene is polymorphic: the −765 C (rather than G) variant of the gene is associated with reduced COX2 activity.

Objective: To test the hypothesis that the C allele of COX2 is associated with worse neurodevelopmental outcomes after premature birth.

Outcomes: Cerebral palsy, disability, Griffith’s developmental quotient at 2 years and British Ability Scales-11 general cognitive ability and motor performance (movement assessment battery for children) at 5½ years were compared with COX2 genotype.

Results: The C allele (GC 65 (31%), CC 3 (1%)) was independently associated with worse cognitive performance at 2 and 5½ years: C allele mean (SEM) developmental quotient 92.7 (1.7), v GG 97.6 (1.5), p = 0.039; C allele mean (SEM) general cognitive ability, 94.3 (2.2) v GG 100.9 (1.7), p = 0.028.

Conclusion: An antineuropathological role for COX2 in the preterm brain may help account for the lack of effect of indomethacin treatment in improving neurocognitive outcomes in children born preterm, despite reported reduction in apparent brain injury.


  • Published Online First xx xx xxxx

  • Funding: This research was supported by awards from the Southmead Hospital Millenium Research Foundation to AW and DRH, and from The British Heart Foundation (grant numbers RG200015, SP98003) to SEH and HEM. The original APIP study was supported by Action Research (grant to NM).

  • Competing interests: None.

Latest from Education & Practice

Latest from Education & Practice

Register for free content

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of ADC Fetal & Neonatal.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article